James Wilding

UK & European Patent Attorney

James’ practice is focused on EPO prosecution and opposition work in the life sciences sector.  He also has extensive experience with supplementary protection certificates (SPCs) and has prosecuted SPC applications covering a number of blockbuster drugs.

Summary

Year joined: 2014

Qualifications: MBiochem DPhil EPA CPA

Expertise

James handles a mix of EPO prosecution and opposition work in the life sciences sector.  He has particular expertise in immunology, including antibody-based therapeutics and vaccines, diagnostics, nucleic acid amplification, (oligo) nucleotide therapy, gene editing and plant extracts.  He is experienced in handling EPO opposition proceedings and regularly appears before EPO tribunals on behalf of clients.  James also has extensive experience with supplementary protection certificates.  He has co-ordinated prosecution of several SPC/paediatric extension portfolios across Europe, and regularly advises clients in this area, including in relation to SPC disputes.

Academic

James has a master's degree in biochemistry and a doctorate on the biochemistry of heart disease, both from Oxford University. James also conducted post-doctoral research at Université Paris-XI on cardiac disease. He is an author of several peer-reviewed papers on this subject.

Membership & Organisations

James is a CIPA fellow and member of the EPI.

Recent Work

Represented opponents at oral proceedings in two therapeutic antibody cases, EP-B-2368913 and EP-B-2241578, leading to revocation of both patents (February and October 2018).  Represented patentee in the successful defence of EP-B-1301538 relating to artificial antibody scaffolds (April 2018).  Represented an opponent in the widely-reported CRISPR-Cas9 case in which the EPO ordered revocation of EP-B-2771468 belonging to the Broad Institute, et al. (January 2018).

Specialisms

  • Patent Applications

  • Patent Enforcement
  • Patent Portfolio Management
  • Patent Oppositions
  • IP Strategy
  • Freedom to Operate
  • Due Diligence



Follow us on twitter